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Abstract
Angiogenesis is an indispensable biological process, any aberrancy associated 
with which can lead to pathological manifestations. To manage different patho-
logical conditions associated with abnormal angiogenesis, Nanomaterial based 
formulations have been tested in in vitro and in vivo models by different groups. The 
research advancements pertaining to the applications of major candidate nanoma-
terials for the treatment of pathologies like tumor, cardiovascular diseases, diabetic 
retinopathy, age related macular degeneration, chronic wounds, impaired osteogen-
esis and nerve tissue degeneration, have been briefed in this chapter.
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1. Introduction
Angiogenesis is an important biological process which involves the development of 
new capillary network from the pre-existing vasculature [1–2]. The process of angio-
genesis is indispensable in supplying oxygen and nutrients to cells under hypoxia, 
and it has been implicated in different physiological processes such as wound healing, 
embryogenesis etc. It has also been reported to play key role in many pathologies 
including diabetic retinopathy and cancer [3]. Angiogenesis is a multi-step process, 
which commences when the primary, pro angiogenic cytokine, VEGF, is secreted by 
the cells experiencing hypoxia. Thereafter the interaction of VEGF with its receptor 
(VEGFR2) on the nearby endothelial cells (EC), leads to EC activation, proliferation, 
migration, extra cellular matrix (ECM) remodeling, tube formation followed by loop 
formation leading finally to neo vessel formation and vascular stabilization [4–5].
The process of angiogenesis is regulated by multiple factors, which may be pro- or 
anti-angiogenic in nature. The endogenous pro angiogenic factors include growth 
factors like VEGF, PDGF, FGF, EGF, angiopoietin-1, interleukin-8, placental growth 
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factor, angiogenin etc. The anti- angiogenic factors include endostatin, angiostatin, 
prolactin, fibronectin, vasostatin, interleukin-12, platelet factor 4 etc. [6–7]. An 
equilibrium exists between the pro- and anti-angiogenic factors under physiological 
conditions, and any disturbance in that equilibrium would result in pathological mani-
festations [3]. Targeting angiogenesis therefore has drawn huge attention with respect 
to the therapeutics of pathologies were excessive or insufficient angiogenesis prevails 
[7]. One of the major approaches in angiogenesis targeted therapy involves targeting 
VEGF signaling pathway. Humanized monoclonal antibody targeting VEGFA, namely, 
Bevacizumab, with the approval of US Food and Drug Administration (FDA), has 
been employed in a combination therapy for the treatment of metastatic colorectal 
cancer [8]. In addition, an aptamer which inhibits VEGF 165, namely, Pegaptanib 
has been approved by FDA to treat Age related macular degeneration [9]. In spite of 
all such interventions, targeting angiogenesis demands much more explorations due 
to a variety of unresolved issues such as development of resistance to antiangiogenic 
therapy, lack of adequate treatment for ischaemic disorders etc. [10].
In an urge to overcome the limitations of conventional angiogenic therapy, 
researchers globally have focused on developing ‘nanomedicines’ for the treatment 
and diagnosis of various diseases associated with aberrant angiogenesis [11]. The 
field of nanomedicine involves the use of nanomaterials for biological and medici-
nal applications by virtue of their ability to interact with nucleic acids, proteins and 
membrane receptors effortlessly [10]. In this chapter, we have therefore focused on 
various research achievements pertaining to candidate nanomaterials that can be 
developed as potential drugs for angiogenic therapy.
2. Nanomaterials
The class of substances having at least one dimension less than 100 nano meters 
are called nanoscale materials and the field of science that deals with the synthesis, 
study of structure, physical and chemical properties and applications of various 
types of nanoscale materials is referred as Nanotechnology [12]. Nanomaterials 
usually occur as zero, one, two and three-dimensional structures. Generally, the 
nanoparticles are comprised of three layers called the surface layer, the shell layer 
and the core. The core is the central portion of the materials surrounded by the shell 
and surface layer. The shell layer is chemically different from the core and the outer 
layer. The surface layer permits surface modification with a variety of moieties like 
polymers, metal ions, and surfactants [13]. The physical and chemical properties 
of bulk materials are independent of their size, however, when converted into nano 
scale materials their optical, physical, mechanical and chemical properties vary 
according to their size [14]. Such properties include solubility, color, toxicity etc. 
The major reason for these improved properties of nanomaterials are due to their 
high surface mass ratio as compared with the bulk [15]. Due to their unique size, 
shape, structure and solubility they have found application in the biomedical, opti-
cal, sensor, electric and energy harvesting fields. Many nanomaterials are already 
being explored for their use in biomedical imaging [16], bio/chemical sensing [17], 
targeted gene and drug delivery [18]. We here focus on candidate nanomaterials 
which are potential nanomedicines in the field of therapeutic angiogenesis.
2.1 Classification of nanomaterials according to chemical composition
Based on the origin, size, morphology and chemical composition, nanomaterials 
are divided into various categories. In the present chapter we are focusing on some 
of the important classes that have found applications in biological field.
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2.1.1 Metal nanoparticles
Metal nanoparticles are those particles which may be the pure metal or metal 
compounds like metal oxide, hydroxides, sulphides etc., exhibit size in the sub-
micron scale. A variety of metal nanoparticles has been synthesized with varied 
structural morphology, size and compositions [19]. These metal nanoparticles can 
be synthesized from various metal precursors and can be functionalized with sev-
eral groups [20]. The metal nanoparticles permit surface modification with various 
chemical functional groups and further allow them to be conjugated with polymers, 
ligands, antibodies etc. The improved surface mass ratio, shape, morphology and 
functionality, quantum confinement and plasmon excitation make them suitable 
for the applications in the field of energy, catalysis, electronics, and medicine 
[21]. However, they show some demerits such as tendency to get agglomerate and 
chances of formation of impurities due to their high reactivity. Many of the nano-
materials except gold, silver, and platinum exhibits high cyto-toxicity.
2.1.2 Carbon-based nanomaterials
Among the various carbonaceous nanomaterials, the zero-dimensional carbon-
based quantum dots (CQDs and GQDs), one-dimensional carbon nanotubes 
(CNTs) and two-dimensional graphene (GR) are currently the most popular 
nanocarbon representatives in biological applications [22]. Carbon-based QDs are 
the recent extension in the nano carbon family with fascinating properties like 
biocompatibility, resistance to photobleaching and attractive photoluminescence. 
These outstanding properties make them smart candidates for bioimaging, sensing, 
drug delivery and cancer therapy [23–24]. CNTs have a unique 1D nanostructure, 
with sp2 hybridized carbon atoms rolled up to design a cylindrical shape. They 
exist as both single-walled CNTs and multi-walled CNTs depending on the number 
rolled-up graphene sheets. Due to their exceptional structural, mechanical, and 
electrical diversities, they deliver remarkable flexibility, strength, and electrical 
properties suitable for various biological applications like medical diagnostics, sens-
ing and treatment of diseases. Graphene represents the 2D nano allotrope of carbon 
illustrating a planar graphitic structure with sp2 hybridized carbon network. Its 
surpassingly large surface area, easy functionalization and chemical purity makes 
it a potential candidate for drug delivery. Moreover, it is also widely explored for in 
vivo imaging and cancer detection.
2.1.3 Polymeric nanoparticles
Polymeric nanoparticles are constructed with the aid of natural or synthetic 
polymers. As compared to other nanoparticles, they offer advantages like non-tox-
icity and biocompatibility suited for specific biological applications. Although they 
are used for biosensing and bioimaging, the major purpose of polymeric nanopar-
ticles lies in the field of drug delivery [25]. Biomolecules or drugs are encapsulated 
into polymeric nanoparticles to obtain a gradual and continuous release of the drugs 
at the specifically targeted sites.
2.1.4 Ceramic nanoparticles
Nanoscale ceramics, which include various ceramic nanoparticles of zirconia, 
hydroxyapatite, alumina and titanium oxide have also found potential biologi-
cal applications. Some of the distinct features like high load capacity, stability 
and effortless incorporation to hydrophilic and hydrophobic systems enhance 
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their efficiency in the field of biomedicine, however, work on scaling down its 
cytotoxicity remains to be addressed before its full-fledged use in the biological 
system [26].
2.1.5 Semiconductor nanoparticles
Semiconductor nanoparticles, particularly QDs have been heavily explored for a 
wide variety of biological applications like biosensing, molecular imaging, live-
cell labelling and drug delivery. They possess unique optical properties like a long 
fluorescence lifetime and low photobleaching when correlated with conventional 
organic dyes and fluorescent polymers [27]. Although, the toxicity of the tradi-
tional semiconductor QDs is a typical concern that has to be addressed for in vivo 
applications.
2.1.6 Lipid-based nanoparticles
Lipid-based nanoparticles, consisting of liposomes, nanostructured lipid car-
riers and solid lipid nanoparticles have gained tremendous attention in the field of 
cancer treatment and drug delivery. These nanoparticles exhibit very low toxicity, 
can act as a carrier for both hydrophilic and hydrophobic molecules and ensures 
controlled release of drugs. Due to its versatility and biocompatibility, liposomes are 
the extensively utilized lipid-based nanoparticles [28].
3.  Nanomaterial mediated therapy for pathologies with aberrant 
angiogenesis
Abnormal or excessive angiogenesis has been reported to be involved in the 
progression of a wide variety of diseases affecting different organs. For example, 
aberrant angiogenesis has been implicated to promote diseases like tumor, auto 
immune disorders and infectious diseases caused by the pathogens inducing 
angiogenesis and such diseases have been reported to affect multiple organ sys-
tems [29]. Further, it has also been reported to be involved in the advancement of 
skin tissue associated diseases like psoriasis, allergic dermatitis, blistering disease, 
scar keloids etc. In addition, it has been reported to be the major cause for diabetic 
retinopathy and choroidal neovascularization associated with wet type AMD, 
which affect the eyes [29]. Abnormal angiogenesis has also been reported to be 
involved in the progression of blood vessel associated disorders like atheroscle-
rosis, transplant arteriopathy etc. [30]. The involvement of angiogenesis has also 
been reported in the progression of primary pulmonary hypertension, asthma 
and nasal polyps [29]. In addition, it has also been reported in the progression of 
diseases that affect the reproductive system, which include ovarian hyper stimula-
tion, endometriosis etc. [31]. Aberrant angiogenesis has also been the leading 
cause for the progression of diseases like osteomyelitis which is characterized by 
impaired osteogenesis [29]. It has also been reported to promote nerve system 
associated diseases like diabetic neuropathy and amyotrophic lateral sclerosis, 
which are characterized by nerve tissue degeneration [32]. The process of angio-
genesis has also been reported to promote physiological processes like wound 
healing and discrepancy associated with that could lead to complications like 
development of chronic wounds [33]. Different candidate disorders associated 
with aberrant angiogenesis and the candidate nanomaterials that can be devel-
oped as potential drugs for the treatment of such disorders have been detailed 
below.
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3.1 Tumor
The essentiality of angiogenesis in the progression of tumor growth was a 
breakthrough finding by Judah Folkman way back in 1971, which opened up an era 
of investigations, concerned with targeting angiogenesis for cancer therapeutics. 
It has been established that a tumor cannot grow beyond 2 mm in diameter with-
out a steady supply of oxygen and nutrients by means of angiogenesis [34–36]. 
Therefore, preventing the neovascularisation has been suggested as one of the key 
strategies for cancer therapeutics. Angiogenesis in a tumor micro environment, 
unlike that under physiological conditions, is characterized by the formation of 
immature, leaky blood vessels, resulting in a continual state of inflammation. This 
happens mainly due to the increased expression of a variety of pro angiogenic 
factors including VEGF, angiopoietin, integrins etc. and such factors are being 
targeted for anti-angiogenic therapy. Anti-angiogenic agents targeting VEGF, such 
as Bevacizumab has been approved by FDA, however, release of other pro angio-
genic factors over ruled the efficiency of such mono-therapies [37–40]. Therefore, 
combination therapies using multiple anti-angiogenic agents were more appreciated 
to quick fix resistance to angiogenic monotherapy.
Nanoparticles (NPs) could be employed as a vehicle to deliver multiple drugs, 
targeting different molecules and pathways associated with tumor angiogenesis 
[37, 41]. The therapeutic drugs are generally loaded on to the NPs either by chemi-
cal conjugation or by encapsulation [38]. The NP-based drug delivery can either 
be passive or active in mode. The presence of leaky blood vessels in the vicinity of 
tumors facilitates the passive extravasation of NPs with size less than 200 nm into 
the tumor site by the Enhanced Permeability and Retention effect (EPR) and such 
NPs are later on cleared by the liver [39, 42]. In addition, limited lymphatic drain-
age facilitates the retention of NPs at the site of tumors which in turn promotes 
sustained drug delivery [39]. It has been reported that NP conjugated Doxorubicin 
[43–44] and small molecule inhibitors of angiogenesis [45] could accumulate in 
the tumor micro environment by EPR effect, which lead to the stoppage of tumor 
angiogenesis and tumor growth [38]. Further, Caplostatin (TNP-470), an angio-
genic inhibitor, has been reported to get selectively piled up in the blood vessels 
associated with tumors by EPR effect which in turn blocked tumor associated 
vascular hyperpermeability [46–47]. The Active targeting of tumor vasculature by 
NPs is achieved by means of ligands presented on NP surfaces. The ligands would 
selectively bind to receptors which are over expressed on tumor cells as well as on 
tumor associated ECs, such receptors include VEGFRs, αvβ3 integrins etc. [38, 48].
NP mediated targeting of different miRNAs have also been tested for their 
therapeutic efficacy [49]. For instance, treatment with NP containing anti-miR-21 
(CTX-SNALP-anti miR-21) has been reported to silence miR-21 in patients with 
glioblastoma resulting in an increase in the levels of its target gene RhoB both at 
mRNA and protein levels. Further, NP mediated administration of anti-miR-21 has 
been reported to inhibit tumor proliferation, induce apoptosis and promote survival 
rate in the animal model [49]. Exosomes are endogenous lipid-based NPs which 
are involved in the transfer of biomolecules like RNA and proteins between cells. 
It has been reported that miR-23a encapsulated exosomes could effectively induce 
angiogenesis in CAM model as well as in in ovo xenograft model by regulating the 
expression of SIRT1 gene [50].
Different metal NPs like gold and silver NPs have been reported to be effective 
for anti-angiogenic therapy. It has been reported that gold NPs (AuNPs) are capable 
of binding to the heparin binding domains of various growth factors like VEGF165 
and bFGF leading to the conformational changes associated with the impaired 
functioning of such growth factors. AuNP mediated inhibition of VEGF was found 
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to be negatively regulating the phosphorylation of VEGFR2. The inhibitory effect 
of AuNPs on Heparin binding growth factors (HB-GFs) was found to be greatly 
depended on the size of AuNPs, further, AuNPs with 20 nm in diameter exhibited 
maximum inhibitory effect. In addition, AuNP with bare surface was found to be 
essential for the inhibitory effect on HB-GFs. Further, AuNPs have been reported to 
block of MAPK pathway in tumor cells which lead to the inhibition of epithelial to 
mesenchymal transition (EMT) and thence, the process of metastasis [51–52].
AuNP has also been used as the carrier tool for drug delivery. It has been used 
to deliver an anti-EMT agent, Quercetin (Qu) and AuNP-Qu was found to be more 
effective when compared to free Qu, in inhibiting cell migration in MDA-MB-23 
and MCF-7 cell lines [53]. In addition, recombinant human endostatin (rhES), an 
anti- angiogenic molecule, which in conjugation with AuNP-PEG (rhES-AuNPs-
PEG), when administrated, targeted tumor cells more efficiently and exhibited 
better performance when compared to rhES. Moreover, the administration of 
rhES-AuNPs-PEG in combination with 5-flouro uracil (5-FU) facilitated improved 
localization of 5-FU on to the tumor site with subsequent reduction in tumor size 
than that in case of mono therapeutic administration of 5FU [54].
Silver NPs (AgNPs) have been reported to inhibit VEGF induced cell pro-
liferation, migration and tube formation in bovine retinal endothelial cells 
(BRECs). It has also been reported to inhibit vessel formation in matrigel plug 
assay system. AgNP mediated anti angiogenic effect was found to involve nega-
tive regulation of PI3K/Akt pathway [55–56]. According to a different study, 
AgNP has been reported to exert anti angiogenic effect by inhibiting HIF-1 in a 
dose dependant manner [57].
In addition to metal NPs, NPs based on cationic polysaccharides like chitosan 
has also been explored for biomedical applications taking an advantage of their 
relatively low toxic nature and high biodegradability and biocompatibility. Chitosan 
NPs (CNPs) showed anti-cancer effect in the xenograft model of hepatocellular car-
cinoma by inhibiting the expression of VEGFR2 and thereby negatively regulating 
the process of tumor angiogenesis [58]. Further, CNPs in conjugation with Ursolic 
acid (CH-UA-NPs) have been shown to inhibit cell migration and tube formation in 
human umbilical vein endothelial cells (HUVECs) in-vitro. In addition, CH-UA-NPs 
have also been reported to inhibit the expression of VEGF in hepatoma cell xeno-
grafts [59]. CNPs have also been utilized as a vehicle for the co delivery of psiRNA 
VEGF and pIL-4 in MCF-7 cells which caused relatively huge reduction in the levels 
of VEGF protein when compared to the cases where the plasmids were used indi-
vidually [60].
Ruthenium modified selenium NPs (Ru-SeNPs) have also been reported to 
exhibit anti angiogenic properties, in CAM model as well as in HUVEC cells, mainly 
by inhibiting the phosphorylation of Akt, FGFR1 and Erk1/2. Further, it has been 
shown that SeNPs protected with Ru (II)-thiols (Ru-MUA@Se) was endocytosed by 
the cells by clathrin mediated mechanism [61]. SeNPs have also been used as a car-
rier tool for siRNA delivery. A pH sensitive, modified SeNP carrying VEGF-siRNA, 
namely, G2/PAH-Cit/SeNPs@siRNA, has been shown to exhibit high efficiency in 
terms of cellular uptake, drug release and gene silencing [62].
The cerium oxide NPs (CONPs) have been reported to exhibit anti-oxidant 
activity and they are characterized by a cerium core and a shield with an oxygen 
lattice. Chen et al., have shown that CONPs are capable of inhibiting reactive 
oxygen species (ROS) induced angiogenic signaling pathways [63]. In addition, 
the nanoceria conjugated with heparin was reported to inhibit the proliferation 
of human coronary artery endothelial cells (HCAECs) in a better way than that 
by unconjugated nanoceria [64]. Nanoceria has also been reported to inhibit the 
7
Regulation of Angiogenesis Using Nanomaterial Based Formulations: An Emerging Therapeutic…
DOI: http://dx.doi.org/10.5772/intechopen.94151
proliferation of ovarian cancer cells in xenograft model in-vivo [65]. Further, the 
nanoceria conjugated with folic acid has also been reported to inhibit proliferation 
and angiogenesis in xenografts of ovarian cancer cells in vivo [66]. The anti-angio-
genic effect imparted by nanoceria was reported to involve the inhibition of VEGF 
signaling pathway leading to the decreased phosphorylation of VEGFR2 at Tyr1173 
and Y951 [65]. However, a report by Das et al., have suggested that nanoceria might 
exhibit pro angiogenic effect also [67], making the use of these NPs as anti-angio-
genic molecules doubtful under clinical setup.
Silica based NPs have also been reported to exhibit anti angiogenic properties. 
Silicate NPs (SiO2 NPs) have been reported to inhibit VEGFR2 phosphoryla-
tion and ERK1/2 activation in human micro vascular retinal endothelial cells 
(HMRECs), thereby inhibiting angiogenesis [68]. Mesoporous silica based 
nanoparticles (MSNs) have been used as a vehicle for the targeted delivery of 
chemotherapeutic agent, doxorubicin hydrochloride (MSNs@DOX). MSNs@
DOX has been reported to suppress the metastasis of lung cancer cells by inhibit-
ing VEGF induced angiogenesis [69]. Further RGD (Arg-Gly-Asp) modified MSN 
has been used as a carrier tool for the targeted delivery of anti-angiogenic agent, 
NAMI-A [70].
Further, MoS2 nanoflakes containing ZnO NPs were found to inhibit tumor 
growth in in-ovo xenograft model by inducing apoptosis and by negatively 
regulating the processes of angiogenesis as well as EMT [71]. Similarly, the 
Tetraiodothyroacetic acid (Tetrac) based NPs have also been reported to be anti-
angiogenic in nature in CAM model and in xenograft model of renal cancer cells 
[72]. Shereema et al., have formulated a green luminescent CQDs, which inhibited 
angiogenesis in CAM model by negatively regulating the expression levels of 
pro angiogenic factors including VEGF and FGF. The CQDs showed anti-cancer 
property in vitro, suggesting it to be a potential drug candidate for targeting tumor 
angiogenesis [73]. The applications of nanomaterials for anti tumor therapy have 
been represented schematically in Figure 1.
Figure 1. 
Applications of nanomaterials in anti-tumor therapy. Many candidate nanomaterials possess intrinsic anti-
angiogenic property and few could be used as vehicles for targeted drug delivery. Nanoparticles encapsulated/
conjugated with anti- angiogenic drugs or nanoparticle based anti-angiogenic scaffolds, when administrated in 
in vivo models, precisely target tumor vasculature and inhibit tumor growth.
Theranostics - An Old Concept in New Clothing
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3.2 Cardio vascular diseases
Cardio vascular diseases (CVDs), which refer to a class of ailments encompass-
ing coronary artery disease (CHD), peripheral arterial disease, cerebrovascular dis-
ease etc., account for the leading cause of death worldwide [74–75]. Atherosclerosis 
is the most prevalent pathology behind CVDs, which involves the local accumula-
tion of cholesterol within the walls of medium and large arteries leading to the 
emergence of atherosclerotic plaque [76–77]. The process of angiogenesis has been 
implicated to play key role in plaque growth and intra plaque hemorrhage leading 
to plaque rapture [78–79]. The application of nanomaterials has found its way in 
the diagnosis as well as treatment of CVDs. Integrin αvβ3 has been found to be over 
expressed in ECs actively involved in angiogenesis, thus, it has been targeted using 
NPs for CVD diagnosis [80]. For instance, in a murine model of hind limb ischemia, 
76Br- labeled multivalent dendrimers conjugated with integrin αvβ3 targeting 
peptides, were utilized for the detection of angiogenesis by positron emission 
tomography-computed tomography (PET-CT) [81]. In a different experiment using 
murine model of hind limb ischemia, a natriuretic peptide receptor C- targeted, 
64Cu labeled NP probe was used for the detection of angiogenesis [82]. Further, 
gadolinium-loaded perfluorocarbon (PFC) NP conjugated with a vitronectin 
antagonist peptide mimic, has been suggested to be a promising candidate for the 
detection of atherosclerotic lesions [83]. In addition, PFC NPs incorporated with 
anti-angiogenic drug, Fumagillin, have been implicated for the treatment of plaque 
angiogenesis [84].
3.3 Chronic wounds
Wounds are the disruption of the normal physiology of the skin, mucosal sur-
faces or organs, which occur as a part of a disease or etiology. The process of wound 
healing is divided into four distinct stages: hemostasis, inflammation, proliferation, 
and tissue remodeling. Injuries that show delayed healing up to 12 weeks after the 
initial insult are termed chronic wounds, often it happens because of various rea-
sons such as persistent pathological inflammation [85], complications of ischemia, 
diabetes mellitus, or chronic venous insufficiency [86]. The application of growth 
factors has been employed to improve wound healing by promoting angiogenesis, 
but it possessed some drawbacks like rapid degradation of the candidate growth 
factors and the lack of controlled and localized delivery system.
Different NPs have been reported to promote wound healing, and many of 
them were implicated as drug carriers. Studies have shown that different metal 
ions-based nanomaterials possess the ability to promote angiogenesis and thereby 
induce wound healing [87–88]. The metal ions such as Sr2+ and Co2+ when combined 
with nano bioactive glass showed pro angiogenic activity [89]. Colloidal AuNPs 
have been widely studied for biomedical applications due to their unique surface 
characteristics as well as optical and electronic properties [90]. AuNPs combined 
with epigallocatechin gallate and α-lipoic acid, reduced oxidative stress and inflam-
mation and augmented angiogenesis, which led to cutaneous wound healing in 
rodent models [91]. The increased surface area of spherical AuNP helps in electron 
acceptance and also in scavenging reactive oxygen species that cause oxidative stress 
and impaired wound healing [92]. Formulation of AuNPs and scrambled peptides 
were reported to be suitable for angiogenic modulation in in vivo and in vitro models 
[93]. Moreover, NPs encapsulated in a microparticle developed by the microfluidic 
method provided a way to introduce a wide range of proteins including pro angio-
genic agents to the injury site [94].
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Low expression levels of angiogenic growth factors lead to impaired angiogene-
sis and wound healing. Heparin mimetic peptide nanofiber scaffolds have been used 
to overcome this situation, which showed improved vascular development associ-
ated with enhanced VEGF production in the treated animals. Also, hierarchically 
micro-patterned nanofibrous scaffolds with a surface modified nanosized bio-glass 
have been implicated in improving wound healing [95]. Xie et al. have developed 
an electrospun fiber nano composites containing different components such as 
antibacterial polymer chitosan, poly (ethylene oxide), VEGF and PDGF-BB loaded 
poly (lactic-co-glycolic acid) NPs. They have demonstrated that the application 
of such a nano composite would prevent bacterial attack in the vicinity of wound. 
In addition, they have demonstrated that the nano composite facilitated the early 
delivery of VEGF from the nanofiber and sustained delivery of PDGF-BB from the 
NPs, thereby accelerating tissue regeneration and remodeling in a full-thickness rat 
skin wound model [96]. Lino et al. have shown that light-responsive plasmonic gold 
nanocarrier could be used as a carrier vehicle for the delivery of microRNAs such 
as miR-302a and miR-155, which regulated the proliferation and survival of ECs 
thereby promoting wound healing [97].
Carbon nanotubes were functionalized with different side-chain moieties 
and they were applied for diagnosis as well as drug delivery purposes [98]. It has 
been shown that the Multi-Walled Carbon Nanotube (MWCNT) supports angio-
genesis as the macrophages engulfing MWCNT, produce angiogenic cytokines 
such as VEGF and MMP9 [99]. Liu et al. have constructed a composite scaffold of 
VEGF165 loaded functionalized MWCNT, for the prolonged and sustained deliv-
ery of VEGF165, and it promoted tissue remodeling and repairing in the in vivo 
 models [100].
Graphene based NPs have also been implicated to have massive applications 
in angiogenesis-based therapeutics [101]. Graphene, graphene oxide (GO) and 
reduced graphene oxide (rGO) have received great attraction as inorganic addi-
tive in biopolymers for developing biomaterial composites [102]. The Gelatin-
methacryloyl (GelMA) hydrogel containing rGO has been indicated to promote cell 
proliferation and migration in in-vitro model of wound healing and it has also been 
implicated to promote angiogenesis in chick embryo model [103]. In addition, ZnO 
nanoflower based nanomaterials [104] and water-soluble CONPs [105] were also 
implicated to exhibit wound healing properties by modulating the process of angio-
genesis. The candidate nanomaterials which possess the ability to promote wound 
healing, by promoting angiogenesis have been indicated schematically in Figure 2.
Figure 2. 
Pro-angiogenic nanomaterials promote wound healing. Nanomaterials like cerium oxide nanoparticles, zinc 
oxide nanoflowers, multi walled carbon nanotubes, reduced graphene oxide nanoparticles and metal ion based 
nanoparticles like strontium ions and cobalt ions, promote wound healing in different in vitro and in vivo 
models by promoting the process of angiogenesis.
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3.4 Diabetic retinopathy and age-related macular degeneration
Diabetic retinopathy (DR) is one of the critical leading causes of blindness and 
it is a secondary complication associated with Diabetic Mellitus. Diabetes affects the 
entire neurovascular regions of the retina, with ongoing neurodegeneration, gliosis, 
neuroinflammation, edema, angiogenesis, and fibrosis [106]. The changes in the 
vasculature cause perceptible abnormality in vision and lead to blindness. VEGFA, 
which gets upregulated in response to hypoxia, plays a central role in the initiation 
of DR. In addition to that, MMP9 has also been implicated to play key role in the 
onset and severity of DR [107].
The Age-related macular degeneration (AMD) is another complication where 
pathological angiogenesis is involved. AMD has been classified into two types. The 
type of AMD which is characterized by yellowish deposits in the macula is known as 
the Dry AMD, whereas, the AMD with characteristic choroidal neovascularisation 
(CNV) is termed as the wet type or neovascular AMD [108].
Laser photocoagulation and multiple intra ocular injections are the treatment 
strategies adopted for the diseases that affect the vascular structure of the posterior 
eye. It has complications like the destruction of healthy tissues. Though ‘introduc-
ing protein drugs’, was put forth as one of the treatment strategies, it possessed 
drawbacks like drug instability due to proteases action followed by drug injection. 
It therefore warranted novel treatment strategies to conquer these drawbacks. So, 
in an effort to develop alternative therapeutic strategies for ocular diseases, the 
efficacy of different candidate NPs, exhibiting innate anti angiogenic property or 
possessing the ability to carry drug, growth factors etc., to specific tissue sites, have 
been tested by different groups [109–110].
The AuNPs, as mentioned earlier, possess anti angiogenic properties in addition 
to their unique electronic, biocompatible, and molecular-recognition properties 
[111]. It has been reported to induce the nano structural reorganization of VEGFR2 
in HUVECs and consequently suppressed angiogenesis [112]. AuNPs have also been 
reported to suppress VEGF induced cell migration by negatively regulating the 
phosphorylation of Akt and eNOS in retinal endothelial cells [113]. It has also been 
reported to obstruct the proliferation of VEGF treated retinal endothelial cells by 
suppressing Src signaling pathways [114].
Kringle 5 (K5), a proteolytic fragment of plasminogen possessing 80 amino 
acids, has been shown to be highly effective in the inhibition of EC growth [115]. It 
has also been reported to inhibit ischemia-stimulated retinal neovascularization in 
the oxygen-induced retinopathy (OIR) model [116]. But it possessed the drawback 
of a short life span. An expression plasmid of K5 was encapsulated with PLGA 
polymer to form nanoparticles (K5-NP) which effectively inhibited VEGF expres-
sion and attenuated ischemia-induced retinal vascular leakage and retinal neovas-
cularization in the OIR rat model [117]. Biodegradable NPs loaded with Fenofibrate 
(Feno-NPs) have been reported to be particularly useful for the targeted delivery 
and treatment of DR and neovascular AMD. Fenofibrate is a peroxisome prolifera-
tor-activated receptor α (PPARα) agonist, which is effective against DR. In diabetic 
rat models, at 8 weeks after the administration of Feno-NP by one intravitreal 
injection, the vascular leakage in the retina was found to be reduced. In addition to 
that the retinal leukostasis was inhibited, and further, the expression of VEGF and 
ICAM-1 were down regulated [118].
Octreotide (OCT), an analog of somatostatin, is an established  neuroprotective 
and anti-angiogenic agent that targets VEGF. The intra ocular delivery of OCT 
combined with Magnetic NPs (MNP-OCT) has been suggested to improve the 
half-life and bio activity of OCT [119]. Polliner et al. have checked the possibility of 
receptor mediated targeting of NPs to capillary endothelial cells in the retina, and 
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they have demonstrated that Cyclo (RGDfC)-modified QDs specifically bind to the 
αvβ3 integrin receptors on the ECs and the cellular uptake mediated by receptor 
binding led to the accumulation of the NPs in the choriocapillaris and intraretinal 
capillaries [120].
Yandrapu et al. have formulated ‘Nanoparticles in Porous Micropaticles 
(NPinPMP)’, by encapsulating bevacizumab coated poly lactic acid NPs into 
porousifying PLGA microparticles (NPinPMP) using supercritical carbon dioxide 
(SC CO2). Bevacizumab is a protein drug used to treat neovascular AMD and it was 
necessary to inject once in a month intravitreally. The in vitro studies revealed that, 
NPinPMP showed a sustained release of bevacizumab for a period of 4 months. In 
addition, bevacizumab has been detected for a period of 2 months after intravitreal 
injection of NPinPMP in rat model, while it was detected only for 2 weeks upon its 
intravitreal administration in individual form [121].
Likewise, Luo et al. have used, biodegradable PLGA nanoparticles conjugated 
with integrin-binding linear RGD peptide, as a carrier tool for the delivery of 
recombinant tFlt23k intraceptor plasmid possessing VEGF binding domains. 
The nontoxic RGD-functionalized NP delivery system was observed to be getting 
targeted directly to the choroidal neovascularization lesions after intravenous injec-
tion, and exhibited excellent vision restoration in both primate and murine AMD 
models [122].
Celecoxib is a cyclooxygenase-2 inhibitor, exhibiting anti-inflammatory and 
anti-angiogenic properties. Celecoxib-loaded poly (ortho ester) NPs were found 
to be highly effective against AMD and DR [123]. Interleukin-12 (IL-12) has been 
reported to exhibit anti-angiogenic property by reducing the levels of MMP9 and 
VEGFA [124]. Zheng and colleagues combined IL-12 with PLGA nanoparticles 
(IL-12-PNP) and proved it to be exhibiting better efficacy in terms of inhibition of 
VEGFA and MMP9 expressions in DR mouse retina and rat ECs. Further, the intra 
ocular administration of IL-12-PNPs showed reduced retinal damage in mice model 
with DR [125].
3.5 Impaired osteogenesis
Osteogenesis is referred to the process of regeneration of bones, which involves 
multiple steps such as the activation, migration and differentiation of different cell 
types [126]. The process of angiogenesis is crucial for the supply of growth factors, 
hormones, cytokines, chemokines, and metabolites required for osteogenesis. Any 
aberrancy associated with the vascular supply to the bone tissues would lead to 
different pathologies such as osteonecrosis [127], osteomyelitis [128], and osteopo-
rosis [129–130]. Discrepancy in angiogenesis has also been reported as one of the 
main reasons for the failure of osteogenesis after implantation. VEGF and HIFα are 
the major angiogenesis related factors that promote osteoblast differentiation and 
osteogenesis. So, it has been suggested that restoring angiogenesis would promote 
bone function and defect repair in pathologies with impaired osteogenesis.
Many candidate nanomaterials have been reported to be effective in improving 
the repair of bone tissues [131]. For example, synthesized chitin–CaSO4–nano-
fibrin based injectable gel system showed enhanced osteo-regeneration via 
enhanced angiogenesis [132]. Further, the β CaSiO3/PDLGA composite has been 
reported to induce the phosphorylation and activation of Akt and eNOS respec-
tively in HUVECs with a resultant increase in the synthesis and release of NO and 
VEGF. Further the bone regeneration study in the rabbit femur defect model using 
β CaSiO3/PDLGA composite has shown enhanced angiogenesis and osteogenesis 
[133]. Nano-hydroxyapatite has been reported to regulate the PI3K/Akt pathway for 
inhibiting migration and tube formation in HUVECs via inhibiting NO synthesis 
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and eNOS phosphorylation [134]. Similarly, calcium phosphate combined with 
electro spun poly (lactic acid) has been reported to promote VEGF expression in 
endothelial cells. It has also been reported to support vascular development and 
bone regeneration when injected subcutaneously in mice, by promoting the expres-
sion of proangiogenic factors like VEGF, IGF-2, GM-CSF, IL-1 beta, IL-6, IL-12p70 
etc. [135]. Similarly, Nano bioactive glass, characterized by higher surface area 
and three-dimensional channel structure, is another material that could promote 
angiogenesis and bone regeneration [136–137].
Nanomaterials can also act as carrier tools for different pro angiogenic 
small molecules and proteins like deferoxamine, adrenomedullin, VEGF etc. 
For example, Mesoporous silicate nanoparticles (MSNs) incorporated-3D 
nanofibrous gelatin (GF) scaffold has been employed for the dual-delivery of 
bone morphogenetic protein-2 (BMP2) and deferoxamine (DFO). DFO, being 
a hypoxia-mimetic drug, could trigger the stabilization of HIF-1α, and initiate 
subsequent angiogenesis. Further, it has been shown that DFO could signifi-
cantly enhance BMP2 induced osteogenic differentiation in mouse and human 
stem cell models [138].
Ionic components have been utilized for the modification of vascularized 
bone tissue engineering scaffold. The Copper based nanomaterials could pro-
mote the expression level of VEGF, which in turn promoted the proliferation 
of ECs. Nano-structured surfaces on the Hydroxyapatite scaffolds in copper 
ion (Cu2+) containing solutions under hydrothermal conditions could affect EC 
proliferation. Further, the nano-structured surfaces on the Hydroxyapatite scaf-
folds, promoted angiogenesis and bone regeneration. Dexamethasone (DEX), 
an osteogenic inducer combined with biphasic calcium phosphate nanoparticle 
(BCP NPs) scaffold, was found to induce the expression of VEGF and VEGFR2 
and supported bone regeneration. The micro-grooves present in the scaffolds 
managed the assembly of HUVECs into tubular structures and promoted angio-
genesis [139]. The gene encapsulated magnetic microspheres have also been used 
as a promising delivery system. For instance, introduction of VEGF165 with 
superparamagnetic (nano-Fe3O4) chitosan, induced in vitro and in vivo angiogen-
esis and bone regeneration [140].
The AuNPs have also been reported to induce angiogenesis during  osteogenesis. 
AuNPs exhibited differences in angiogenic activity based on their surface charges 
and the presence of functional groups. The Gene profiling data revealed that 
in comparison with the cells (hMSCs) treated with AuNPs possessing amine or 
hydroxyl functional groups (AuNPeNH2 or AuNPeOH), the cells treated with 
carboxyl group containing AuNPs (AuNPeCOOH) showed augmented expression 
levels of TGFβ and FGF-2, which in turn promoted cell proliferation over osteogenic 
differentiation [141].
3.6 Nerve tissue degeneration
Nerve tissue degeneration is a critical clinical challenge that leads to diseases like 
trauma or permanent paralysis, so research advancement in the field of nerve tissue 
regeneration is quite necessary. In the recent years, the applications of nanomateri-
als have received much attention from the research community focusing on nerve 
tissue repair.
The process of angiogenesis plays key role in supplying nutrients to the nerve 
tissue which in turn helps to repair segmental nerve defects. Recently, Lopez-
Dolado et al. have designed a 3D scaffold containing partially reduced graphene 
oxide, which when implanted in the injured site in the spinal cord of a rat model, a 
remarkable induction in angiogenesis and axon regeneration was observed [142]. 
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Further, GO/polycaprolactone (PCL) nano scaffolds have been implicated to 
promote angiogenesis by modulating Akt-eNOS-VEGF signaling pathway and it 
facilitated peripheral nerve regeneration in-vivo [143].
In addition, Xu et al. have formulated an acellular spinal cord scaffold 
(ASCS), namely, V-ASCS, for the sustained delivery of VEGF, and it was com-
posed of VEGF165 encapsulated PLGA nanoparticles conjugated with ASCS. 
When V-ASCS was implanted at the injury site in a rat spinal cord hemisection 
model, it rendered significant progress in neovascularization [144]. Wen et al. 
fabricated a hyaluronic acid scaffold with brain-derived neurotrophic factor and 
VEGF loaded PLGA microspheres, which promoted angiogenesis and nerve fiber 
regeneration when implanted at the injured site in the spinal cord of rat model 
[145]. Yu and his co-workers have formulated PLGA microspheres encapsulated 
with VEGF, angiopoietin-1 and bFGF, and these angiogenic microspheres could 
release the angiogenic factors in a sustained fashion, which then induced angio-
genesis and neurogenesis when administered at the injured site in the spinal cord 
of rat model [146].
Jian et al. have fabricated a nanohybrid hydrogel containing sulfated glycos-
aminoglycan-based polyelectrolyte complex nanoparticles (PCN), and it could 
accelerate neurogenesis and angiogenesis in in-vivo ischemic stroke model [147]. 
Amorphous non-fibrous hydrogel comprised of hyaluronic acid containing high 
cluster VEGF, when injected directly within the stroke cavity, stimulated the forma-
tion of a vascular and neuronal structures, that preceded to behavioral improve-
ment in vivo [148].
Delivery of superparamagnetic iron oxide nanoparticle labeled Endothelial 
progenitor cells (EPCs) was found to induce the formation of vessel-like structures 
by the production of VEGF and FGF [149]. Similarly, superparamagnetic iron oxide 
(SPIO)-Au core-shell NPs incorporated with nerve growth factor (NGF) have been 
implicated to promote neuron growth and differentiation [150].
4. Conclusion
Aberrancy associated with angiogenesis pave the way for the progression of a 
number of diseases like tumor, cardio vascular diseases, diabetic retinopathy, age 
related macular degeneration etc. So, targeting angiogenesis presents itself as one of 
the key therapeutic strategies to tackle such complications. The currently available 
therapies though beneficial, do possess some limitations like acquisition of drug 
resistance by cells, fast decay of protein drugs by protease action, off target effects 
leading to decreased drug efficacy etc. Different candidate nanomaterials were 
implicated to possess anti- angiogenic properties, which were tested in vitro and 
in vivo to explore their additional properties like precise targeting of pathological 
angiogenesis, cellular uptake, efficacy etc. Nanoparticles have also been utilized 
as carrier tools for drug delivery. Surface modification of nanoparticles with 
RGD, VEGF etc. has reinforced them with specific targeting, internalization and 
sustained drug delivery. Growth factor encapsulated nanoparticle-based scaffolds 
were fabricated by different groups, to effectuate wound healing, osteogenesis 
and nerve tissue regeneration in in vivo models. On the whole, the application of 
nanomaterial-based formulations in pro or anti angiogenic therapy is a rewarding 
strategy for the treatment of complications associated with aberrant angiogenesis, 
which however, requires more explorations for translating from bench to bedside. 
The candidate disorders associated with aberrant angiogenesis and various applica-
tions of nanomaterials for the treatment of such disorders have been represented 
schematically in Figure 3.
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Figure 3. 
Nanomaterial based formulations for the treatment of pathological conditions with aberrant angiogenesis. 
Abnormal angiogenesis promotes the progression of different diseases like tumor, cardiovascular disease, chronic 
wounds, diabetic retinopathy, wet type age related macular regeneration, bone and nerve tissue degeneration 
etc. nanomaterials possessing intrinsic pro- or anti- angiogenic property could be utilized individually or 
as a part of biodegradable polymer based-scaffolds for the treatment of such disorders. Different candidate 
nanoparticles with surface modifications with peptides like arginine-glycine-aspartate (RGD) and vascular 
endothelial growth factor (VEGF), could be utilized as carrier tools for targeted drug delivery.
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